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ABSTRACT 
Elevated intraocular pressure (IOP) is an important risk factor for glaucoma. Mechanisms involved in 
its homeostasis are not well understood, but associations between metabolic factors and IOP have 
been reported. To investigate the relationship between levels of circulating metabolites and IOP, we 
performed a metabolome-wide association using a machine learning algorithm, and then employing 
Mendelian Randomization models to further explore the strength and directionality of effect of the 
metabolites on IOP. We show that O-methylascorbate, a circulating Vitamin C metabolite, has a 
significant IOP-lowering effect, consistent with previous knowledge of the anti-hypertensive and anti-
oxidative role of ascorbate compounds. These results enhance understanding of IOP control and may 
potentially benefit future IOP treatment and reduce vision loss from glaucoma. 
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1. Introduction  
Glaucoma is a leading cause of irreversible blindness and an important public health concern.  Better 
understanding of its pathophysiology is important because it might lead to earlier detection and 
improved management strategies. Glaucoma and intraocular pressure (IOP) are tightly correlated 
genetically and epidemiologically[1], but our understanding of cell and tissue-level processes underlying 
elevated IOP and glaucoma are not well understood.  
The eyes share cellular metabolic pathways and physiological mechanisms with other organs and 
tissues. Genes associated with IOP and POAG are involved, among others, in systemic lipid 
metabolism[1, 2], lysosomal endocytosis[3] and angiogenesis[1, 4]. Additionally, both IOP[5] and 
POAG[6] are strongly associated with the components of the metabolic syndrome (hyperglycemia, 
hyperlipidemia and high systemic blood pressure).  
The purposes of this work were to investigate the relationship between circulating metabolites and IOP, 
by performing a metabolome-wide association study, and to examine the causality direction of such 
relationships, using Mendelian Randomization (MR) in independent population-based cohorts.  
2 Materials and Methods 
2.1 Study design.  
This work followed two stages. First, associations between circulating metabolite levels of individual 
metabolites and IOP were identified in a population-based cohort (TwinsUK). Subsequently, Mendelian 
Randomization (MR) analyses in two independent populations were used to validate the relationship 
between circulating metabolite levels and IOP and assess causality. 
 
 
2.2 Populations and subjects 
2.2.1 TwinsUK.  
This is a volunteer cohort recruited from the general population in the United Kingdom[7]. Included in 
this study are 1,763 adults (684 twin pairs and 395 singletons), for whom both metabolite levels and eye 
measurements including IOP were available.  
The IOP measurements were taken using a non-contact air-puff tonometer (Ocular Response Analyzer, 
ORA, Reichert, Buffalo, NY). The mean IOP was calculated from four readings (two from each eye). 
Subjects who were receiving IOP-lowering medications or had IOP-altering surgery were excluded from 
the analyses.   
2.2.2 UK Biobank.  
UK Biobank is a large multisite cohort study of UK residents aged 40 to 69 years. Participants’ IOP was 
measured once per eye using ORA. Participants with a history of eye surgery or injury and with IOP 
measurements in the top and bottom 0.5 percentiles were excluded.  The pre-treatment IOP of the 
1,571 participants under IOP-lowering medication was imputed as 130% of the measured mean IOP to 
allow for medication effect as previously recommended [8-10].  IOP was calculated as the mean of right 
and left eye ORA IOPcc parameter values for each participant.  Effect size estimations for subsequent 
MR analyses were extracted from the results of association between genotypes and IOP, described 
elsewhere[1]. 
2.2.3 EPIC-Norfolk.  
EPIC-Norfolk is one of the UK arms of the European Prospective Investigation into Cancer (EPIC) 
study[11].  Detailed ophthalmic assessments using ORA and genotypes were available for 8,623 
participants. The quality control, inclusion and exclusion criteria, QC steps and linear regression methods 
that were used to generate results, are described in detail elsewhere[1].  
 
2.2.4 Ethical Approvals 
This study was conducted in accordance with the principles of the Declaration of Helsinki and the 
Research Governance Framework for Health and Social Care. All participants gave informed consent 
after appropriate ethics committee approval: Guy’s and Saint Thomas (GSTT) for the TwinsUK, the 
North-West Research Ethics Committee for the UK Biobank and the Norfolk Local Research Ethics 
Committee and East Norfolk & Waveney NHS Research Governance Committee for the EPIC-Norfolk 
participants.   
2.3 Metabolite measurements 
Non-targeted metabolite detection and quantification was conducted using the platform provided by 
Metabolon Inc. (Durham, USA) on fasting plasma samples as previously described [12].  Quality control 
steps for the 529 measured metabolites are reported elsewhere[12], and they included batch-effect 
data normalization, outlier (>4SD) removal and subsequently inverse-normalization[13]. Only 313 
metabolites that were measured in at least 90% of subjects were included in analyses.  
2.4 Statistical Analyses 
2.4.1 Random Forest analysis of metabolite effects on IOP  
Although metabolites may be univariably associated with genetic factors, their ratios and other higher-
order forms of interaction between more than one metabolite have physiologic relevance and are under 
tight genetic control [12]. Simple linear regression models therefore are incapable of fully modelling 
these interactions. Here, we employed a Random Forest[14] machine learning technique (RF) which 
agnostically identifies the metabolites that are most influential over an outcome, regardless of the 
specific model through which the effect is mediated. These models implicitly capture higher order 
interactions between variables[15]. We used RF to rank all available metabolites according to the 
Breiman-Cutler “VIMP” values[14]. Importance ranking has no associated probabilities, or formal 
thresholds of significance, nor any need for multiple-testing correction as long as all variables are tested 
jointly at the same time. To control for bias from predictor variables’ (metabolites) differing 
variances[16], all variables were standard inverse-normalized as previously described [13]. The ‘mtry’ 
parameter was fine-tuned to minimize the out-of-bag errors. The parameters of the RF analyses were 
set as nTree=10,000 and maxNodes=10 and mtry =140. The models also included confoundants such as 
ages at IOP measurement and when the blood samples were drawn, body height and weight, but only 
the relative importance of metabolites over IOP measurements is being reported. Specifically, the model 
included a mixed model adjustment term to address the family relationships among the participants of 
the TwinsUK cohort. 
Analyses reported here were conducted using all available metabolites that passed QC; analyses on 
subsets of unrelated metabolites (not shown) did not produce fundamental alterations in the 
importance ranking of the metabolites representing their clusters. Analyses were run in the 
‘randomForestSRC’ package, version 2.5.1 in R 3.4.1(www.cran.r-project.org). 
2.4.2 Mendelian Randomization comparisons of genetic effects.  
We aimed to validate the findings and assess causality for the most important metabolite identified in 
the RF analysis stage, through an MR model. We used as instrumental variables (IV) SNPs that associated 
with plasma metabolite levels (exposure) on IOP (outcome). 
Effects of genetic variants over metabolite levels were obtained from a published study[12]. We used 
SNPs that showed association at either GWAS-significant (p<10-08), but also at suggestive levels (p<10-06) 
in the final published joint meta-analyses[12]. Estimates of effect sizes and standard errors for the 
association between the selected SNPs and metabolites were from the Kooperative 
Gesundheitsforschung in der Region Augsburg (KORA) cohort and were obtained from previously 
published reports [17]. Only SNPs that were independent (on different chromosomes or at least 4 
million base pairs apart and r2<0.1) were used for the analyses. Estimated effect sizes and standard 
errors for association of the SNPs with IOP were obtained from a GWAS of 103,382 European 
participants of the UK Biobank and separately from 6,595 participants in the EPIC-Norfolk study, as 
reported elsewhere[1].  
Three MR methods were used: inverse variance weighted median, inverse-variance weighted and MR-
Egger. These analyses are usually interpreted together to jointly evaluate the relationship between 
exposure and outcome [18, 19] and don’t require multiple testing correction. The MR-Egger regression 
test intercept evaluates evidence for directional pleiotropy; intercepts significantly different from the 
origin suggest directional pleiotropy, where the underlying Instrument Strength Independent of Direct 
Effect (InSIDE) assumption may not be satisfied[20]. Analyses were performed using the 
‘MendelianRandomization’ R package[21].  
3 Results  
3.1 O-methylascorbate levels are associated with IOP 
We studied the plasma levels of 313 metabolites in the dataset of 1,772 TwinsUK participants, for whom 
IOP measurements were also available. The main demographic and clinical characteristics of the sample 
are summarized in Table 1.  
A random forest (RF) analysis ordered metabolites according to the importance of their association with 
IOP (Figure 1). The highest-ranking metabolite in order of importance was O-methylascorbate[22].  This 
is a known metabolic product of the L-ascorbic acid (Vitamin C) [23]. Polymorphic changes of the 
sequences of the COMT, but also KLF12, SIL1, FDFT1 and PPPC5 genes are associated with O-
methylascorbate levels[12]. The second ranking metabolite from the RF analysis was alpha-
hydroxyvalerate, an amino acid metabolite. High in the rankings (Supplementary Table 1) were also 
carnitine, involved in lipid transfer across the mitochondrial membrane[24] and phenylacetylglutamine, 
a metabolite of glutamate, an antioxidative stress marker. 
3.2 O-methylascorbate reduces IOP in independent populations 
We followed up on the highest-ranking metabolite from the RF analysis. To validate results, we explored 
the relationship between O-methylascorbate and IOP in two independent populations. We used as 
genetic instruments single nucleotide polymorphisms (SNPs) that were significantly associated with O-
methylascorbate levels in the KORA cohort[12], and examined their association with IOP, initially, in the 
UK Biobank cohort (Supplementary Table 2). A Mendelian Randomization (MR) model found a significant 
relationship between exposure (the O-methylascorbate levels) and IOP. All three models (Table 2, Figure 
2a) showed a statistically significant inverse relationship between the circulating levels of this 
metabolite and IOP (weighted median p=0.02, robust IVW p=2.4x10-10 and RM-Egger p=3.33x10-06). 
There was no statistical evidence of pleiotropy (MR-Egger Intercept=0.00).  We further used the same 
instrumental variables(IVs) to build a second MR model in another independent dataset. The MR results 
in the EPIC-Norfolk dataset were consistent with the results obtained in the UK Biobank, with 
statistically significant effects of O-methylascorbate on IOP (Table2 and Figure 2b).  
To further exclude pleiotropy, we reversed our MR models to use IOP as the putative risk, SNPs 
significantly associated with IOP, described elsewhere[1] (Supplementary Table 3) as IVs, IOP as 
exposure and O-methylascorbate as the outcome of interest. In contrast to the previous results, none of 
the tests were statistically significant (Supplementary Table 4), which further suggests that O-
methylascorbate levels causally affect IOP and not vice versa. 
 
4 Discussion 
Here we report, for the first time, that O-methylascorbate, a Vitamin C metabolite, is part of metabolic 
mechanisms that control IOP in the general population. Previous works suggested that levels of Vitamin 
C are reportedly inversely correlated with systemic[25] and pulmonary[26, 27] blood pressure, as well as 
IOP [28, 29]. Although it also enhances endothelial function[30], much of its anti-hypertensive effects 
are likely mediated by its powerful antioxidative properties, which provide protection from the radical 
oxygen species [31].  
Photooxidative stress in the eye leads to trabecular meshwork degradation[32], elevated IOP due to 
increased aqueous outflow resistance[33] and ultimately glaucoma[34]. Vitamin C is highly concentrated 
in the aqueous humor forms the first line of defense against free radicals in the eyes[35]. The O-
methylascorbate, a naturally occurring metabolite, is less cytotoxic [36] and has a strong reductive 
capacity against photooxidative stress[37].  
Our study combined metabolomic and genetic data to identify metabolic processes that modulate IOP in 
healthy populations. Our MR results shows that genetic factors that raise O-methylascorbate levels are 
associated with lower IOP. For example, the rs4680 G allele leads to higher COMT activity[38], and 
increased enzymatic conversion of Vitamin C into O-methylascorbate [12]. This variant is also associated 
with lower IOP, likely through the antioxidant properties of its enzymatic reaction product. The 
correlations of effects observed over several genes that independently control O-methylascorbate levels 
suggests that O-methylascorbate effect on IOP is real and not the result of confounding. 
Several considerations are needed for the correct interpretation of these findings. First, O-
methylascorbate effects over IOP homeostasis are likely modest and not deterministic. The metabolome 
platform that we used, only provides semi-quantitative results, but its standard-normalized output may 
be used to assess the strength of statistical associations, but not reliable effect size estimation. Second, 
the metabolomic platform we used only assesses a fraction of the metabolites present in complex 
organisms and could have overlooked metabolites equally or more relevant to IOP homeostasis. Third, 
the TwinsUK discovery cohort had power limitations and is almost exclusively female, while associations 
between oxidative biomarkers and glaucoma were reportedly stronger in men[29]. Finally, while the 
causal inference statistical methods suggest a causative role for O-methylascorbate in IOP, MR 
methodologies critically rely on several assumptions, whose violations would change the interpretation 
of causality [19]. Until further experimental confirmation experimental, the relationship of O- 
methylascorbate with IOP is simply probabilistic.  
Our study demonstrates that Vitamin C metabolism is involved in the control of intraocular pressure. 
These findings provide an additional insight into the role antioxidative stress-related mechanisms in 
intraocular, and maybe blood pressure homeostasis.  Further work will be necessary to establish the 
exact mechanisms of pressure reduction via ascorbate metabolites and establish whether these 
mechanisms may have any role for the clinical management of IOP or glaucoma. 
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Table 1. Main demographic and clinical characteristics of the participating cohorts. Mean and standard 
deviations are given for each parameter; missing values (“NA”) are used for variables not measured in a 
particular cohort. 
 
 TwinsUK UK Biobank EPIC-Norfolk 
Variable 
Mea
n 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Age at the time IOP was 
measured (years) 
55 9.13 
54.4 7.8 68.8 8 
Age when blood samples 
were taken (years) 
58.4 9.87 
NA NA NA NA 
Sex (women : men) 
1,75
5: 8 
NA 
55,103: 
48,279 NA 
3,725:3
,059 NA 
Mean intraocular pressure 
(mmHg) 
15.6 3.18 
16.1 3.5 16.8 3.6 
Central corneal thickness 
(µm) 
544.
9 
39.58 
NA NA - - 
Weight (kg) 
69.4
5 
13.6 
77.98 15.9 74.2 14.1 
Height (cm) 
161.
8 
6.16 
170.1 9.4 166.4 9.1 
 
 
 
Table 2. Mendelian Randomization (MR) study results for IOP in the UK Biobank and EPIC-Norfolk 
cohorts. For each of the three methods used, the β estimate, standard errors (SE) and associated p-
values are reported. The Penalized robust MR-Egger intercept is not a MR model, but if different from 0 
would provide evidence of directional pleiotropy and potential violation of the instrumental variable 
assumptions. 
 UK Biobank EPIC 
Method Beta SE p-value Beta SE p-value 
Penalized weighted median -0.696 0.304 0.022 -3.219 1.371 0.019 
Robust inverse-variance weighted -0.674 0.106 2.04x10-10 -2.891 0.678 2.5x10-05 
Robust MR-Egger -0.637 0.137 3.33x10-06 -4.536 0.689 4.6x10-11 
Penalized robust MR-Egger (Intercept) -0.001 0.006 0.855 0.048 0.026 0.071 
 
 
 
 Figure 1. Plot of the VIMP parameter (relative importance) of the associations with IOP of 313 
metabolite variables tested in the Random Forest analysis.  The metabolites with highest importance 
are labeled (X- 12063 uncharacterized metabolite, identity unknown).  
 
 
 
 
 
 
 
 
Figure 2. Relationship of observed effect sizes of the instrumental variable SNP on IOP in the UK 
Biobank (a) and the EPIC-Norfolk (b) cohorts with the effect sizes of the same SNPs on O-
methylascorbate levels in the KORA population. The lines represent the regression slopes for the 
different models, as specified in the legend. 
 a)          b) 
  
 
 
Highlights: 
 Vitamin C and its metabolites are important regulators of blood and intraocular pressure 
and are highly concentrated in human brain and eye tissues. 
 Multi-omics evidence from metabolomic and genome-wide association studies find 
evidence for association between ascorbic acid metabolism and intraocular pressure. 
 O-methylascorbate lowers intraocular pressure in the general population. 
 The role of this ascorbic metabolite in intraocular pressure regulation likely mediated by 
its anti-photooxidative properties. 
